CD19 and congenital rubella syndrome: (31), early use of corticosteroids plus tocilizumab for low-grade CRS after CD19 CAR-T therapy may significantly reduce progression from low- to high-grade CRS, without worsening the incidence and severity of ICANS or the outcome of CAR-T therapy.